Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

3.500 -0.270 (-7.16%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Amylyx Pharma Stock Hinges On This FDA Action — Here's What To Know
Amylyx is facing an FDA advisory committee Wednesday that will vote on its ALS drug. 
Via Investor's Business Daily
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Amylyx Pharmaceuticals Stock Trading Halted Today
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Shares Plummet On Skeptical FDA Adcomm Docs On ALS Drug
Via Benzinga
50 Biggest Movers From Yesterday
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) shares gained 81.3% to close at $2.32 on Monday. Last week, AMC Entertainment Holdings purchased a major stake in... 
Via Benzinga
Mid-Day Market Update: Crude Oil Dips 8%; Plantronics Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Dow dropping 175 points on Monday. 
Via Benzinga
35 Stocks Moving In Monday's Mid-Day Session
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) jumped 57.1% to $1.96 following reports regarding potential future investments from AMC CEO, Adam Aron.... 
Via Benzinga
Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment
Amylyx Pharmaceuticals could face an uphill battle for its ALS treatment this week. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on AMX0035
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Mid-Morning Market Update: Markets Mixed; SAIC Profit Tops Views
U.S. stocks traded mixed this morning, with the Dow dropping around 100 points on Monday. 
Via Benzinga
Opening Day: AN2 Therapeutics Rises In Public Debut After Upsized IPO
Shares of AN2 Therapeutics rose over 15% in its trading debut on Friday following an upsized initial public offering. This was only the second initial public offering this month, as the IPO market... 
Via Talk Markets
Stocks That Hit 52-Week Lows On Monday
On Monday, 147 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
IPO Stock Amylyx Pharmaceuticals Broke Down — But Just Wait For Its Encore
Here's why a former breakdown stock, Amylyx, has run up for two consecutive days. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
7 Biotech Stocks With Key Catalysts in March
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. 
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios... 
Via Benzinga
Amylyx Pharmaceuticals Announces EMA Validation of Marketing Authorisation Application (MAA) for AMX0035 for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Expands Executive Team with Appointment of Gina M. Mazzariello as Chief Legal Officer and General Counsel
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
80 Biggest Movers From Yesterday
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) jumped 78.5% to close at $0.6066 on Tuesday after jumping 36% on Monday. CTI BioPharma Corp. (NASDAQ: CTIC) surged 63... 
Via Benzinga
FDA Sets Up Adcomm To Review Amylyx's ALS Drug Next Month
The FDA's Peripheral and Central Nervous System Drugs Advisory Committee will review Amylyx Pharmaceuticals Inc's (NASDAQ: AMLX) marketing application for... 
Via Benzinga
73 Biggest Movers From Yesterday
Gainers Imperial Petroleum Inc. (NASDAQ: IMPP) jumped 63.1% to close at $0.80 on Tuesday after declining around 7% on Friday. Indonesia Energy Corporation Limited (NYSE... 
Via Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... 
Via Benzinga
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers Indonesia Energy Corporation Limited (NYSE: INDO) jumped 75.2% to $7.87. Imperial Petroleum Inc. (NASDAQ: IMPP) rose 52.9% to $0.7500 after declining around 7% on Friday... 
Via Benzinga
Amylyx Pharmaceuticals Announces FDA Advisory Committee Meeting to Review New Drug Application for AMX0035 for the Treatment of ALS Scheduled for March 30, 2022
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
70 Biggest Movers From Friday
Gainers Sky Harbour Group Corporation (NYSE: SKYH) shares jumped 48.4% to close at $10.09 on Friday. RISE Education Cayman Ltd (NASDAQ: REDU) gained 39.7% to settle at $0.95.... 
Via Benzinga
Amylyx Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
47 Biggest Movers From Yesterday
Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share. Anghami Inc. (NASDAQ: ANGH... 
Via Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.